Which has better valuation & earnings, AIMDW or HUMAW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ainos $18.11K N/A N/A N/A N/A Humacyte $2.02M N/A N/A N/A N/A

Is AIMDW or HUMAW more profitable?

Company Net Margins Return on Equity Return on Assets Ainos N/A N/A N/A Humacyte N/A N/A N/A

Which has preferable valuation & earnings, ALVOW or HUMAW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alvotech $559.42M N/A N/A N/A N/A Humacyte $2.02M N/A N/A N/A N/A

Is ALVOW or HUMAW more profitable?

Company Net Margins Return on Equity Return on Assets Alvotech N/A N/A N/A Humacyte N/A N/A N/A

Which has higher earnings and valuation, HUMAW or ARAV?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.02M N/A N/A N/A N/A Aravive N/A N/A N/A -$0.90 N/A

Is HUMAW or ARAV more profitable?

Company Net Margins Return on Equity Return on Assets Humacyte N/A N/A N/A Aravive N/A N/A N/A

Which has preferable earnings and valuation, ACABW or HUMAW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atlantic Coastal Acquisition Corp. II N/A N/A N/A N/A N/A Humacyte $2.02M N/A N/A N/A N/A

Is ACABW or HUMAW more profitable?

Company Net Margins Return on Equity Return on Assets Atlantic Coastal Acquisition Corp. II N/A N/A N/A Humacyte N/A N/A N/A

Which has better earnings and valuation, BFRIW or HUMAW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $43.20M N/A N/A N/A N/A Humacyte $2.02M N/A N/A N/A N/A

Is BFRIW or HUMAW more profitable?

Company Net Margins Return on Equity Return on Assets Biofrontera N/A N/A N/A Humacyte N/A N/A N/A

Humacyte (HUMAW) Competitors

$0.0092 0.00 (-13.26%)

As of 02:14 PM Eastern

Compare

HUMAW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Humacyte stock or one of its competitors? MarketBeat compares Humacyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Humacyte include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Humacyte compare to Ainos?

Ainos (NASDAQ:AIMDW) and Humacyte (NASDAQ:HUMAW) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	N/A	N/A	N/A
Humacyte	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$18.11K	N/A	N/A	N/A	N/A
Humacyte	$2.02M	N/A	N/A	N/A	N/A

In the previous week, Ainos had 1 more articles in the media than Humacyte. MarketBeat recorded 2 mentions for Ainos and 1 mentions for Humacyte. Humacyte's average media sentiment score of 1.87 beat Ainos' score of 1.43 indicating that Humacyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Ainos	Positive
Humacyte	Very Positive

Summary

Humacyte beats Ainos on 2 of the 3 factors compared between the two stocks.

How does Humacyte compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Humacyte (NASDAQ:HUMAW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	N/A	N/A	N/A
Humacyte	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$559.42M	N/A	N/A	N/A	N/A
Humacyte	$2.02M	N/A	N/A	N/A	N/A

In the previous week, Alvotech had 1 more articles in the media than Humacyte. MarketBeat recorded 2 mentions for Alvotech and 1 mentions for Humacyte. Humacyte's average media sentiment score of 1.87 beat Alvotech's score of 0.93 indicating that Humacyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Alvotech	Positive
Humacyte	Very Positive

Summary

Alvotech beats Humacyte on 2 of the 3 factors compared between the two stocks.

How does Humacyte compare to Aravive?

Humacyte (NASDAQ:HUMAW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	N/A	N/A	N/A
Aravive	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.02M	N/A	N/A	N/A	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Humacyte had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Humacyte and 0 mentions for Aravive. Humacyte's average media sentiment score of 1.87 beat Aravive's score of 0.00 indicating that Humacyte is being referred to more favorably in the media.

Company	Overall Sentiment
Humacyte	Very Positive
Aravive	Neutral

Summary

Humacyte beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Humacyte compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Humacyte (NASDAQ:HUMAW) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A
Humacyte	$2.02M	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A
Humacyte	N/A	N/A	N/A

In the previous week, Humacyte had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for Humacyte and 0 mentions for Atlantic Coastal Acquisition Corp. II. Humacyte's average media sentiment score of 1.87 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Humacyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Atlantic Coastal Acquisition Corp. II	Neutral
Humacyte	Very Positive

Summary

Humacyte beats Atlantic Coastal Acquisition Corp. II on 3 of the 3 factors compared between the two stocks.

How does Humacyte compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Humacyte (NASDAQ:HUMAW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$43.20M	N/A	N/A	N/A	N/A
Humacyte	$2.02M	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	N/A	N/A	N/A
Humacyte	N/A	N/A	N/A

In the previous week, Biofrontera had 1 more articles in the media than Humacyte. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for Humacyte. Humacyte's average media sentiment score of 1.87 beat Biofrontera's score of 1.44 indicating that Humacyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Biofrontera	Positive
Humacyte	Very Positive

Summary

Biofrontera beats Humacyte on 2 of the 3 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HUMAW vs. The Competition

Export

Metric	Humacyte	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$499.36M	$6.83B	$12.42B
Dividend Yield	N/A	3.87%	2.67%	6.11%
P/E Ratio	N/A	3.17	25.83	24.32
Price / Sales	N/A	6,787.21	549.34	102.14
Price / Cash	N/A	13.13	29.09	36.93
Price / Book	N/A	89.82	10.95	6.47
Net Income	N/A	-$96.07M	$3.58B	$336.72M
7 Day Performance	N/A	1.13%	2.66%	0.67%
1 Month Performance	N/A	-0.24%	0.35%	-0.58%
1 Year Performance	N/A	72.00%	35.74%	30.43%

Humacyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HUMAW Humacyte	N/A	$0.01 -13.3%	N/A	-97.3%	$0.00	$2.02M	N/A	150	Positive News Gap Up High Trading Volume
AIMDW Ainos	N/A	$0.10 -28.3%	N/A	-20.5%	$0.00	$18.11K	N/A	40	Positive News Short Interest Decrease Gap Down
ALVOW Alvotech	N/A	$0.33 flat	N/A	N/A	$0.00	$559.42M	N/A	4	Positive News
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.00 flat	N/A	N/A	$0.00	N/A	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HUMAW) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humacyte (HUMAW) Competitors